Atlas FDA

Trilogy Evo and Trilogy Evo O2 Material Numbers BL2110X15B BR2110X18B CA2110X12B DE2100X13B DE2110X13B DS2100X11B DS2110

FDA device recall Z-0638-2024 · posted 2024-01-04 · Open, Classified

Recall details

Recalling firm
Philips Respironics, Inc.
Reason for recall
The following was missing from the Contraindications Statement: The AVAPS-AE therapy mode is contraindicated for invasive use and patients less than 10 kg. The AVAPS feature is contraindicated for patients less than 10 kg. Potential harms if devices are used on contraindicated patients include barotrauma, hypoventilation/hypercapnia, and rebreathing of excessive CO2.
Action taken
On November 27, 2023, the firm sent "URGENT Medical Device Correction" letters to dated November 20, 2023, affected customers along with an attached manual addendum for insertion into current manuals. Customers were instructed to keep a copy of the letter and attached addendum with their Trilogy Evo or Trilogy Evo O2 Ventilator IFUs. Distributors were instructed to notify any customers to whom they have distributed affected devices. If you need any further information or support concerning this issue, please contact your local Philips representative: Call 1-(877)-387-3311 or email at patientsupport@philips.com
Root cause
Device Design
Status
Open, Classified
Product code
CBK
Quantity affected
100,126 (54,691 US; 45,435 OUS) in total
Distribution
Worldwide distribution: US (nationwide)-AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD,
Date initiated
2023-11-27
Date posted
2024-01-04
Location
Murrysville, PA

Monitor recalls programmatically

Recalls and clearances share one API, with change alerts when new recalls post.

Related 510(k) clearances

RecordFirmDate
Trilogy Evo (K181166)Respironics, Inc.2019-07-18